Inhaled Agonists of Soluble Guanylate Cyclase Induce Selective Pulmonary Vasodilation
- 1 December 2007
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 176 (11) , 1138-1145
- https://doi.org/10.1164/rccm.200707-1121oc
Abstract
Rationale: Nitric oxide–independent agonists of soluble guanylate cyclase (sGC) have been developed. Objectives: We tested whether inhalation of novel dry-powder microparticle formulations containing sGC stimulators (BAY 41-2272, BAY 41-8543) or an sGC activator (BAY 58-2667) would produce selective pulmonary vasodilation in lambs with acute pulmonary hypertension. We also evaluated the combined administration of BAY 41-8543 microparticles and inhaled nitric oxide (iNO). Finally, we examined whether inhaling BAY 58-2667 microparticles would produce pulmonary vasodilation when the response to iNO is impaired. Methods: In awake, spontaneously breathing lambs instrumented with vascular catheters and a tracheostomy tube, U-46619 was infused intravenously to increase mean pulmonary arterial pressure to 35 mm Hg. Measurements and Main Results: Inhalation of microparticles composed of either BAY 41-2272, BAY 41-8543, or BAY 58-2667 and excipients (dipalmitoylphosphatidylcholine, albumin, lactose) produced dose-dependent pulmonary vasodilation and increased transpulmonary cGMP release without significant effect on mean arterial pressure. Inhalation of microparticles containing BAY 41-8543 or BAY 58-2667 increased systemic arterial oxygenation. The magnitude and duration of pulmonary vasodilation induced by iNO were augmented after inhaling BAY 41-8543 microparticles. Intravenous administration of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), which oxidizes the prosthetic heme group of sGC, markedly reduced the pulmonary vasodilator effect of iNO. In contrast, pulmonary vasodilation and transpulmonary cGMP release induced by inhaling BAY 58-2667 microparticles were greatly enhanced after treatment with ODQ. Conclusions: Inhalation of microparticles containing agonists of sGC may provide an effective novel treatment for patients with pulmonary hypertension, particularly when responsiveness to iNO is impaired by oxidation of sGC.Keywords
This publication has 28 references indexed in Scilit:
- MECHANISMS UNDERLYING RELAXATION OF RABBIT AORTA BY BAY 41‐2272, A NITRIC OXIDE‐INDEPENDENT SOLUBLE GUANYLATE CYCLASE ACTIVATORClinical and Experimental Pharmacology and Physiology, 2005
- Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery CellsAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Efficacy and optimal dose of sildenafil in primary pulmonary hypertensionInternational Journal of Cardiology, 2005
- Inhaled alternatives to nitric oxideCritical Care Medicine, 2005
- Inhaled Nitric OxideCirculation, 2004
- Large Porous Particles for Sustained Protection from Carbachol-Induced Bronchoconstriction in Guinea PigsPharmaceutical Research, 1999
- Recent advances in pulmonary drug delivery using large, porous inhaled particlesJournal of Applied Physiology, 1998
- Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase.1996
- Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats.Journal of Clinical Investigation, 1996
- Inhaled Nitric Oxide for the Adult Respiratory Distress SyndromeNew England Journal of Medicine, 1993